Phase III Study of S-1 + Cisplatin Compared With Single-Agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix.
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Registrational; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 02 Jun 2017 Primary endpoint (Overall survival) has been met, as per results published at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 Results comparing efficacy and safety of S-1 plus Cisplatin with those of Cisplatin alone presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 21 Aug 2016 Status changed from active, no longer recruiting to completed.